Cancer Immunotherapy Market: Rapidly Evolving Industry…… COVID-19….
The global cancer
immunotherapy market size is
likely to reach USD 126.9 billion by
2026, according to a new report by Grand View Research, Inc., exhibiting a
CAGR of 9.6% during the forecast period. Increasing patient pool and higher
mortality rate are augmenting the need for cancer immunotherapy globally.
Furthermore, increasing number of approvals for new immunotherapeutic drugs is
driving the global market.
Multiple therapeutic regimens are being
followed across the globe in attempts to come up with a reliable treatment for
Covid-19. One line of treatment includes the use of hydroxychloroquine, while a
second treatment line focuses to use antiviral drugs used in the disease
management of HIV. Both these approaches have surged demand from advanced
antivirals and antimalarial drugs. This impacts the drug manufacturers as an
off label indication for these drug classes has to be worked upon. At the
moment, the WHO has not prescribed any of these approaches, neither they have
commented if one is better than the other. The report will account for Covid19
as a key market contributor.
Cancer immunotherapy has emerged as a
new avenue for revenue generation for pharmaceutical companies. In addition,
adverse effects, such as recurrence of cancer and organ failure, associated
with conventional chemotherapies and rising demand for technologically advanced
healthcare solutions are boosting the demand for immunotherapies. Moreover,
introduction of newer drug classes, such as target receptors for multiple
myeloma and checkpoint inhibitors, is poised to make way for advanced
therapeutics in the market.
Introduction of new molecules has been
proving to be beneficial for patients who are not responding to chemotherapy.
Several new immunotherapeutic options, such as immunomodulators and CAR-T cell
therapy, are in the pipeline and are being tested for their ability to provide
better cancer treatment.
To Request Sample Copy of this report, click the link:
Monoclonal antibodies are the most
widely used immunotherapeutic drugs globally. Development of monoclonal
antibodies as effective immunotherapeutic options started after the approval of
Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell
lymphoblastic leukemia. Increasing R&D pertaining to the use of monoclonal
bodies as naked antigen binding antibodies, conjugated, and bispecific
antibodies is resulting in discovery of new therapeutic options for cancer
treatment.
Further key findings from the report
suggest:
·
Majority of immunotherapy drugs
are being used in treatment of cancer of lung, breast, and prostate
·
Monoclonal antibodies emerged
as the largest segment because of increasing regulatory approvals and higher
efficacy
·
Lung cancer accounted for the
largest share in 2018 and will continue to dominate the market through 2026
·
North America was the leading
revenue contributor in the market in 2018. Rising incidence of cancer and
increasing demand for novel technologies are facilitating the dominance of the
region during the forecast period
·
Europe is projected to witness
rapid growth during the forecast period owing to rapid adoption of advanced
cancer therapeutics for effective treatment
·
Some of the key players are
Amgen, Inc.; AstraZeneca; F. Hoffmann La Roche Ltd.; Bayer AG; Bristol-Myers
Squibb Company; Eli Lilly and Company; Merck and Co., Inc.; Novartis AG; and
Pfizer, Inc.
The
global cancer immunotherapymarket size was valued at USD 58.1 Billion in 2018.
Growing adoption of advanced cancer therapeutic options coupled with rising
cancer incidence has been one of the primary growth stimulants for the market.
Healthcare providers are focusing on improving cancer therapeutic facilities
and reduction in reoccurrence rate of tumor post chemotherapy.
Rising
R&D activities in the cancer immunotherapy field is resulting in
introduction of advanced variants with enhanced efficacy and effectiveness of treatment.
Immuno-oncologics have shown promising results with improved survival and lower
toxicity. A paradigm shift from traditional chemotherapies to immunotherapies
is propelling the overall market.
Immunotherapies
in the pipeline are likely to provide more treatment choices and better
outcomes than existing therapies. Introduction of newer drug classes, such as
monoclonal antibodies and histone deacetylase (HDAC) inhibitors, designed to
target receptors related to multiple myeloma, is poised to shape the future of
the market. Ongoing studies on similar drugs intended to minimize adverse
effects are projected to spur the growth of the market.
In
addition, approval of PD-1 and CTLA-4 checkpoint inhibitors for melanoma and
Non-Small Cell Lung Cancer (NSCLC) has been boosting the growth of the market.
Approval of innovative immunotherapy drug forms, such as vaccines and
adjuvants, is on a rise. Moreover, more immunotherapies are being tested for
enhanced outputs, such as immunomodulators and CAR T-cell therapy. These new
approvals and ongoing research are anticipated to stimulate the growth of the
market over the forecast period.
Have any Query? Ask our Experts:
Grand View Research has segmented the
global cancer immunotherapy market based on product, cancer type:
Cancer Immunotherapy Product Outlook (Revenue, USD
Billion, 2015 - 2026)
·
Monoclonal Antibodies
·
Immunomodulators
·
Oncolytic Viral Therapies and
Cancer Vaccines
Cancer Immunotherapy Cancer Type Outlook (Revenue, USD
Billion, 2015 - 2026)
·
Lung Cancer
·
Breast Cancer
·
Colorectal Cancer
·
Melanoma
·
Prostate Cancer
·
Head and Neck Cancer
·
Ovarian Cancer
·
Pancreatic Cancer
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
Comments
Post a Comment